1.Clinical Imageologic Analysis of Multiplemyeloma(A Report of 43 Cases)
Zhongrong DENG ; Longxiao WEI ; Miaowang HAO ; Renan CHEN
Journal of Practical Radiology 2001;0(06):-
Objective To increase the recognition and diagnostic rate of multiple myeloma.Methods 43 patients with multiple myeloma confirmed by medula needle biopsy and/or pathology were reviewed.Results Misdiagnosis rate reached 65%.Bone abnormality was not found on X-ray and CT films in 8 cases,the remained 35 cases showed bone destructions in varied degrees and types.Conclusion It's main way for improving diagnostic rate of multiple myeloma that deepen recognition of multiple myeloma.Clinical diagnosis must be combined with imageology,laboratory and pathology.
2.Expression of Egr-1 gene in human hepatocellular carcinoma tissues
Miaowang HAO ; Yanfang LIU ; Yingrui LIANG ; Mingyao WU ; Huanxing YANG ; Xianying WU
Chinese Journal of Clinical and Experimental Pathology 2001;(1):49-52
To investigate the role of Egr-1 in the carcinogcnestic process of hepatocellular carcinoma (H-CC). Methods Expression of Egr-1 gene in HCC tissues were detected by in situ hybridization and immunohistochemistry. Human breast andmouse liver and brain tissues were used for control. ResultsLittle or no Egr-1 transcription was detected both in HCC tissues and in their normal counterparts. High transcription of Egr-1 was detected in the LCD and atrophic-like liver plate of HCC tissues. Protein expression of Egr-1 gene was consistent with mRNA transcription. High expression of Egr-1 protein was also detected in normal breast and mouse brain tissues. ConclusionsLittle or no expression of Egr-1 may play a role in the deregulation of normal growth in the carcinogenestic process of HCC. The differences of Egr-1 expression among liver cells, breast epithelia and mouse brain tissues might be associated with their different ways of proliferation and differentiation in different cell types.
3.Treatment to high-risk acute non-lymphocytic leukemia with sequential induction
Guohui LI ; Li LIU ; Miaowang HAO ; Renan CHEN ; Siyong HUANG ; Jincheng WANG ; Fang XIAO ; Huanxu GUO ; Ying WANG ; Hui QI ; Meng WANG ; Jingyi ZHANG ; Hua HE ; Yingmin LIANG
Journal of Leukemia & Lymphoma 2011;20(3):147-150
Objective To investigate the outcome of high-risk acute non-lymphocytic leukemia treated with sequential low-dose cytarabine and harringtonine(LD-HA) and standard induction. Methods 50 high-risk ANLL. patients (LD-HA group) who were regarded as unfit for intensive chemotherapy were chosen to receive LD-HA. Reinductive treatments with standard regimens would be given for those who did not achieve complete remission. 23 patients DA/HA group given two cycles of standard inductive regimens were taken as the control. Results In LD-HA group 80.0 %. (40/50) reached CR, 2 patients died shortly after inductive therapy. The median leukemia-free survival(LFS) was 19.6 months, and the median overall survival (OS) was 12.2 months. Overall survival was 57.0 % at 1 year, 24.1% at 3 years, and 18.8 % at 5 years. While the CR rate was 73.9 % for DA/HA group, and none died during the inductive therapy. LFS and OS was 19.8 months and 12.1 months, respectively. OS rate was 56.58 % at 1 year, 27.1% at 3 years, and 27.1% at 5 years.There were no difference on OS rates between 2 groups (x2 were 0.009, 0.237 and 1.807, respectively,P >0.05). Conclusion In patients who were unfit for intensive chemotherapy, sequential therapy with LD-HA and standard induction improved the rate of complete remission and the duration of survival.